Heron Therapeutics (NASDAQ:HRTX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Heron Therapeutics (NASDAQ:HRTX) from a hold rating to a sell rating in a research report released on Saturday morning.

A number of other research firms have also recently issued reports on HRTX. Zacks Research cut Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Tuesday, April 21st. Finally, HC Wainwright reissued a “buy” rating on shares of Heron Therapeutics in a research note on Monday, May 11th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $4.50.

Heron Therapeutics Price Performance

Heron Therapeutics stock opened at $0.85 on Friday. The firm has a market capitalization of $160.89 million, a P/E ratio of -4.72 and a beta of 1.70. Heron Therapeutics has a 1 year low of $0.74 and a 1 year high of $2.30. The business has a 50-day moving average of $0.95 and a 200-day moving average of $1.14. The company has a current ratio of 2.53, a quick ratio of 1.51 and a debt-to-equity ratio of 17.51.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, May 11th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The company had revenue of $34.71 million for the quarter, compared to analyst estimates of $36.72 million. On average, equities analysts anticipate that Heron Therapeutics will post -0.05 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP bought a new position in shares of Heron Therapeutics in the third quarter worth $5,357,000. Citigroup Inc. increased its position in shares of Heron Therapeutics by 4,666.9% in the third quarter. Citigroup Inc. now owns 2,476,529 shares of the biotechnology company’s stock worth $3,120,000 after purchasing an additional 2,424,576 shares during the period. JW Asset Management LLC increased its position in shares of Heron Therapeutics by 40.8% in the third quarter. JW Asset Management LLC now owns 3,292,633 shares of the biotechnology company’s stock worth $4,149,000 after purchasing an additional 954,890 shares during the period. New York State Common Retirement Fund increased its position in shares of Heron Therapeutics by 46.4% in the third quarter. New York State Common Retirement Fund now owns 2,576,716 shares of the biotechnology company’s stock worth $3,247,000 after purchasing an additional 816,671 shares during the period. Finally, Clearline Capital LP increased its position in shares of Heron Therapeutics by 1,033.1% in the third quarter. Clearline Capital LP now owns 9,712,527 shares of the biotechnology company’s stock worth $12,238,000 after purchasing an additional 8,855,361 shares during the period. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.